Published in Circ J on July 01, 2007
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
Higher serum uric acid on admission is associated with higher short-term mortality and poorer long-term survival after myocardial infarction: retrospective prognostic study. Croat Med J (2009) 0.94
Uric acid and dementia in community-dwelling older persons. Dement Geriatr Cogn Disord (2009) 0.93
The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease. Cardiovasc Psychiatry Neurol (2009) 0.86
Association of serum bilirubin with ischemic stroke outcomes. J Stroke Cerebrovasc Dis (2008) 0.86
Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus. Exp Diabetes Res (2011) 0.85
Association between uric acid levels and obstructive sleep apnea syndrome in a large epidemiological sample. PLoS One (2013) 0.84
Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance. Front Biosci (Landmark Ed) (2009) 0.81
The profile of risk factors and in-patient outcomes of stroke in Kumasi, Ghana. Ghana Med J (2014) 0.78
Platelet count and early outcome in patients with spontaneous cerebellar hemorrhage: a retrospective study. PLoS One (2015) 0.77
Serum uric acid levels and cerebral microbleeds in patients with acute ischemic stroke. PLoS One (2013) 0.77
The role of uric acid as a potential neuroprotectant in acute ischemic stroke: a review of literature. Neurol Sci (2015) 0.76
Lower serum uric acid level strongly predict short-term poor functional outcome in acute stroke with normoglycaemia: a cohort study in China. BMC Neurol (2017) 0.75
Off target effects of statins shape total mortality? J Drug Assess (2016) 0.75
Highly Prevalent Hyperuricaemia is Associated with Adverse Clinical Outcomes Among Ghanaian Stroke Patients: An Observational Prospective Study. Ghana Med J (2015) 0.75
Gout, not hyperuricemia alone, impairs left ventricular diastolic function. Arthritis Res Ther (2015) 0.75
Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des (2011) 4.16
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother (2012) 2.01
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Time for new indications for statins? Med Sci Monit (2009) 1.87
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. J Psychosom Res (2010) 1.54
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
Comparison of the five 2011 guidelines for the treatment of carotid stenosis. J Vasc Surg (2012) 1.51
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis? Angiology (2009) 1.47
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
The role of Toll-like receptors in renal diseases. Nat Rev Nephrol (2010) 1.42
Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology (2012) 1.40
Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. Ann Hematol (2004) 1.39
Optimal statin type and dosage for vascular patients. J Vasc Surg (2011) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors? Ann Allergy Asthma Immunol (2007) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Platelet activation in bypass surgery for critical limb ischemia. Vasc Endovascular Surg (2007) 1.38
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res (2012) 1.33
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol (2011) 1.27
Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci U S A (2010) 1.27
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol (2008) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens (2013) 1.22
The prevalence of metabolic syndrome in various populations. Am J Med Sci (2007) 1.19
Epidemiological survey for the prevalence of overweight and abdominal obesity in Greek adolescents. Obesity (Silver Spring) (2008) 1.19
Drug-induced fibrotic valvular heart disease. Lancet (2009) 1.19
Response to 'Red blood cell distribution width is a predictor of readmission in cardiac patients'. Clin Cardiol (2013) 1.14
Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. J Diabetes Complications (2008) 1.14
Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol (2010) 1.14
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int (2011) 1.12
Vascular risk factors in South Asians. Int J Cardiol (2008) 1.11
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol (2010) 1.10
HSP 70 and atherosclerosis--protector or activator? Expert Opin Ther Targets (2009) 1.10
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int (2011) 1.10
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09
Lone atrial fibrillation: what do we know? Heart (2009) 1.08
Clinical relevance of postprandial lipaemia. Curr Med Chem (2005) 1.08
Pleiotropic effects of statins--clinical evidence. Curr Pharm Des (2009) 1.08
The effect of smoking on arterial stiffness. Hypertens Res (2010) 1.07
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". Dig Liver Dis (2012) 1.06
Statins: a sine qua non of the management of patients with abdominal aortic aneurysms. Int J Cardiol (2013) 1.06
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf (2008) 1.05
Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: Incidence and correlation with disease severity and survival. Hepatol Res (2010) 1.05
Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol (2013) 1.04
An update on biomarkers of heart failure in hypertensive patients. J Hypertens (2012) 1.04
The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res (2009) 1.03
Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. J Gastroenterol Hepatol (2009) 1.03
Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem (2003) 1.03
Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol (2010) 1.03
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des (2010) 1.02
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin (2010) 1.01
What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother (2011) 1.01
Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des (2011) 1.01
Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des (2007) 1.01
Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets (2010) 1.01
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther (2007) 1.01
Metformin and cancer: licence to heal? Expert Opin Investig Drugs (2010) 1.01
Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol (2012) 1.01
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother (2008) 1.00
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res (2013) 1.00
The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. J Urol (2006) 1.00
Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod (2011) 1.00
Metabolic syndrome and renal disease. Int J Cardiol (2012) 0.99
The role of serotonin in tumour growth (review). Oncol Rep (2005) 0.99
Early vascular benefits of statin therapy. Curr Med Res Opin (2003) 0.99
Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke (2005) 0.99